{"product_id":"global-enzyme-linked-immunosorbent-assay-elisa-market-growth-status-and-outlook-2023-2029","title":"Global Enzyme-Linked Immunosorbent Assay (ELISA) Market Growth (Status and Outlook) 2023-2029","description":"\u003cp\u003eGlobal Enzyme-Linked Immunosorbent Assay (ELISA) Market Growth (Status and Outlook) 2023-2029\u003c\/p\u003e\n\n\u003cp\u003eELISAs (Enzyme-linked immunosorbent assays) are routinely used for the qualitative and quantitative assessment of cytokines, chemokines, growth factors, phosphorylated targets, immunoglobulins and other immunological markers. Detection and quantitation of protein analytes from various biological samples—serum, plasma, cell culture supernatants and cell lysates—indicate a multitude of biological and pathological events. ELISAs have proven to be valuable tools in drug development as they are commonly used for biomarker profiling of disease vs. normal states, as well as toxicity profiling.\u003c\/p\u003e\n\n\u003cp\u003eLPI (LP Information)' newest research report, the “Enzyme-Linked Immunosorbent Assay (ELISA) Industry Forecast” looks at past sales and reviews total world Enzyme-Linked Immunosorbent Assay (ELISA) sales in 2022, providing a comprehensive analysis by region and market sector of projected Enzyme-Linked Immunosorbent Assay (ELISA) sales for 2023 through 2029. With Enzyme-Linked Immunosorbent Assay (ELISA) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Enzyme-Linked Immunosorbent Assay (ELISA) industry.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report provides a comprehensive analysis of the global Enzyme-Linked Immunosorbent Assay (ELISA) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M\u0026amp;A activity. This report also analyzes the strategies of leading global companies with a focus on Enzyme-Linked Immunosorbent Assay (ELISA) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Enzyme-Linked Immunosorbent Assay (ELISA) market.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Enzyme-Linked Immunosorbent Assay (ELISA) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Enzyme-Linked Immunosorbent Assay (ELISA).\u003c\/p\u003e\n\n\u003cp\u003eThe global Enzyme-Linked Immunosorbent Assay (ELISA) market size is projected to grow from US$ 175.1 million in 2022 to US$ 226.3 million in 2029; it is expected to grow at a CAGR of 3.7% from 2023 to 2029.\u003c\/p\u003e\n\n\u003cp\u003eGlobal Enzyme-Linked Immunosorbent Assay (ELISA) key players include R\u0026amp;D Systems, Thermo Fisher Scientific, Ortho Clinical Diagnostics, BD Biosciences, etc. Global top four manufacturers hold a share over 45%.\u003c\/p\u003e\n\n\u003cp\u003eChina is the largest market, with a share over 35%, followed by Europe, and USA, both have a share over 30 percent.\u003c\/p\u003e \n\n\u003cp\u003eIn terms of product, Indirect ELISA is the largest segment, with a share over 45%. And in terms of application, the largest application is Immunology, followed by Infectious Diseases, Protein Quantitation, Cancer, etc.\u003c\/p\u003e\n\n\u003cp\u003eThis report presents a comprehensive overview, market shares, and growth opportunities of Enzyme-Linked Immunosorbent Assay (ELISA) market by product type, application, key players and key regions and countries.\u003c\/p\u003e\n\n\u003cp\u003eMarket Segmentation:\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by type\u003c\/p\u003e\n\n \u003cp\u003eSandwich ELISA\u003c\/p\u003e\n\n \u003cp\u003eIndirect ELISA\u003c\/p\u003e\n\n \u003cp\u003eCompetitive ELISA\u003c\/p\u003e\n\n \u003cp\u003eOthers\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by application\u003c\/p\u003e\n\n \u003cp\u003eImmunology\u003c\/p\u003e\n\n \u003cp\u003eInflammation\u003c\/p\u003e\n\n \u003cp\u003eInfectious Diseases\u003c\/p\u003e\n\n \u003cp\u003eCancer\u003c\/p\u003e\n\n \u003cp\u003eProtein Quantitation\u003c\/p\u003e\n\n \u003cp\u003eOthers\u003c\/p\u003e\n\n\u003cp\u003eThis report also splits the market by region:\u003c\/p\u003e\n\n \u003cp\u003eAmericas\u003c\/p\u003e\n\n \u003cp\u003eUnited States\u003c\/p\u003e\n\n \u003cp\u003eCanada\u003c\/p\u003e\n\n \u003cp\u003eMexico\u003c\/p\u003e\n\n \u003cp\u003eBrazil\u003c\/p\u003e\n\n \u003cp\u003eAPAC\u003c\/p\u003e\n\n \u003cp\u003eChina\u003c\/p\u003e\n\n \u003cp\u003eJapan\u003c\/p\u003e\n\n \u003cp\u003eKorea\u003c\/p\u003e\n\n \u003cp\u003eSoutheast Asia\u003c\/p\u003e\n\n \u003cp\u003eIndia\u003c\/p\u003e\n\n \u003cp\u003eAustralia\u003c\/p\u003e\n\n \u003cp\u003eEurope\u003c\/p\u003e\n\n \u003cp\u003eGermany\u003c\/p\u003e\n\n \u003cp\u003eFrance\u003c\/p\u003e\n\n \u003cp\u003eUK\u003c\/p\u003e\n\n \u003cp\u003eItaly\u003c\/p\u003e\n\n \u003cp\u003eRussia\u003c\/p\u003e\n\n \u003cp\u003eMiddle East \u0026amp; Africa\u003c\/p\u003e\n\n \u003cp\u003eEgypt\u003c\/p\u003e\n\n \u003cp\u003eSouth Africa\u003c\/p\u003e\n\n \u003cp\u003eIsrael\u003c\/p\u003e\n\n \u003cp\u003eTurkey\u003c\/p\u003e\n\n \u003cp\u003eGCC Countries\u003c\/p\u003e\n\n\u003cp\u003eThe below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.\u003c\/p\u003e\n\n \u003cp\u003eR\u0026amp;D Systems\u003c\/p\u003e\n\n \u003cp\u003eThermo Fisher Scientific\u003c\/p\u003e\n\n \u003cp\u003eOrtho Clinical Diagnostics\u003c\/p\u003e\n\n \u003cp\u003eBD Biosciences\u003c\/p\u003e\n\n \u003cp\u003eZEUS Scientific\u003c\/p\u003e\n\n \u003cp\u003eBio-Rad Laboratories\u003c\/p\u003e\n\n \u003cp\u003eALPCO\u003c\/p\u003e\n\n \u003cp\u003eEnzo Life Sciences\u003c\/p\u003e\n\n \u003cp\u003eBioMérieux\u003c\/p\u003e\n\n \u003cp\u003eEMD Millipore\u003c\/p\u003e\n\n \u003cp\u003eBioLegend\u003c\/p\u003e\n\n \u003cp\u003eLOEWE Biochemica\u003c\/p\u003e\n\n \u003cp\u003eMercodia\u003c\/p\u003e\n\n \u003cp\u003eCusabio\u003c\/p\u003e\n\n \u003cp\u003eShanghai Kehua Bio-engineering\u003c\/p\u003e\n\n\u003cp\u003ePlease note: The report will take approximately 2 business days to prepare and deliver.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"January, 2023 \/ 113 Pages \/ MCW16225932","offer_id":47640099619122,"sku":null,"price":4392.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-enzyme-linked-immunosorbent-assay-elisa-market-growth-status-and-outlook-2023-2029","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}